Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 30

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic106Crohn's disease94Colorectal cancer90Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma40Adenocarcinoma pancreas36Pancreatic carcinoma metastatic35Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome31Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Colorectal adenocarcinoma16Endometrial cancer16+450

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Pancreatic carcinoma metastatic

Recruiting

Study on Valproic Acid, Simvastatin, and Gemcitabine for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Rectal cancer

Recruiting

Study of Durvalumab with Drug Combination for Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Grupo Espanol Multidisciplinar En Cancer Digestivo

Adenocarcinoma gastric

Recruiting

Study on Pressurized Intraperitoneal Aerosol Chemotherapy with Fluorouracil for Patients with Gastric Cancer with Peritoneal Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Gastrointestinal cancer metastatic

Recruiting

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Small intestine adenocarcinoma

Recruiting

Study on the Effectiveness of Fluorouracil, Levoleucovorin, and Oxaliplatin in Patients with Resected Small Bowel Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Groupe Belge D'Oncologie Digestive

Appendicitis+1

Recruiting

Study on Post-Surgery Antibiotic Use in Patients with Complicated Acute Appendicitis: Evaluating Metronidazole, Ceftriaxone, and Ofloxacin Hydrochloride

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceftriaxone Sodium
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Gastric cancer

Recruiting

Study on Pre-operative Capecitabine, Oxaliplatin, Docetaxel, and Atezolizumab for Patients with Resectable Gastric or Gastro-esophageal Junction Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Inguinal hernia

Recruiting

Study on Pain Relief for Patients with Inguinal Hernia: Comparing Ropivacaine Hydrochloride TAP Block and Sodium Chloride Local Infiltration

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:UZ Brussel

Systemic scleroderma

Recruiting

Study on the Safety of Allogeneic Adipose-Derived Mesenchymal Stromal Cells for Patients with Severe Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Mesenchymal Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Assistance Publique Hopitaux De Paris

Adenocarcinoma gastric

Recruiting

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EXL01
  • Sponsor:Association Gercor

Atypical haemolytic uraemic syndrome

Recruiting

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Malignant peritoneal neoplasm+2

Recruiting

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil207 clinical trialsOxaliplatin197 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate69 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate53 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.